593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts)
Loh J, Choo J, Sooi K, Low P, Ang C, Sundar R, Walsh R, Wijaya S, Low J, Hsing S, Jain S, Chee C. 593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Annals Of Oncology 2023, 34: s429. DOI: 10.1016/j.annonc.2023.09.1784.Peer-Reviewed Original Research